## RX 801077 hydrochloride

Cat. No.:	HY-100904	
CAS No.:	89196-95-2	
Molecular Formula:	C <sub>11</sub> H <sub>11</sub> CIN <sub>2</sub> O	
Molecular Weight:	222.67	
Target:	Imidazoline Receptor	
Pathway:	Neuronal Signaling	H–Cl
Storage:	4°C, sealed storage, away from moisture	
	* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)	

## SOLVENT & SOLUBILITY

In Vitro

DMSO : 20.83 mg/mL	(93.55 mM; ultraso	nic and warr	ning and heat to 60°C)	

	Solvent Mass Concentration	1 mg	5 mg	10 mg
Preparing Stock Solutions	1 mM	4.4910 mL	22.4548 mL	44.9095 mL
	5 mM	0.8982 mL	4.4910 mL	8.9819 mL
	10 mM	0.4491 mL	2.2455 mL	4.4910 mL

Please refer to the solubility information to select the appropriate solvent.

	ТУ	
DIOLOGICALACITY		
Description	RX 801077 hydrochloride hydrochlorideshows ant traumatic brain injury (T	e (2 BFI) is a selective imidazoline I2 receptor (I2R) agonist with a K <sub>i</sub> value of 70.1 nM. RX 801077 i-inflammation and neuroprotection. RX 801077 hydrochloride has the potential for the research of BI) <sup>[1][2]</sup> .
IC <sub>50</sub> & Target	K <sub>i</sub> : 70.1 nM (imidazoline	12 receptor) <sup>[1]</sup>
In Vivo	RX 801077 hydrochloride and necroptosis in a rat i MCE has not independer	e (5, 10, 20 mg/kg; i.p.; twice daily for 3 days) inhibits NLRP3 inflammasome-induced inflammation model of traumatic brain injury <sup>[2]</sup> . htly confirmed the accuracy of these methods. They are for reference only.
	Animal Model:	280-300 g, Male adult Sprague-Dawley rats (TBI model) <sup>[2]</sup>
	Dosage:	5, 10, 20 mg/kg
	Administration:	I.p.; twice daily for 3 days



Ν

**Product** Data Sheet

Result:	Attenuated neurological deficits, brain edema, BBB permeability and cortical tissue loss in
	a rat model of TBI, reduced microglial activation, neutrophil infiltration, and
	proinflammatory cytokine IL-1 $eta$ secretion, reduced the expression of RIP1 and RIP3 in
	neurons in the pericontusional cortex.

## REFERENCES

[1]. Carpéné C, et al. Inhibition of amine oxidase activity by derivatives that recognize imidazoline I2 sites. J Pharmacol Exp Ther. 1995 Feb;272(2):681-8.

[2]. Ni H, et al. 2-BFI Provides Neuroprotection Against Inflammation and Necroptosis in a Rat Model of Traumatic Brain Injury. Front Neurosci. 2019 Jun 26;13:674.

## Caution: Product has not been fully validated for medical applications. For research use only.

 Tel: 609-228-6898
 Fax: 609-228-5909
 E-mail: tech@MedChemExpress.com

 Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA